Healthcare Value Capital’s Cytokinetics CYTK Stock Holding History

Healthcare Value Capital’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-100,000	Closed	-$918K	–	22
2016 Q3	$918K	Hold	100,000	–	–	1.45%	14
2016 Q2	$949K	Hold	100,000	–	–	1.15%	14
2016 Q1	$705K	Hold	100,000	–	–	1.04%	18
2015 Q4	$1.05M	Hold	100,000	–	–	1.73%	13
2015 Q3	$669K	Hold	100,000	–	–	0.95%	20
2015 Q2	$672K	Hold	100,000	–	–	0.71%	25
2015 Q1	$678K	Hold	100,000	–	–	0.74%	25
2014 Q4	$801K	Buy	+100,000	New	+$429K	1.46%	15
2014 Q3	–	Sell	-41,666	Closed	-$199K	–	34
2014 Q2	$199K	Sell	41,666 -15,000	-26%	-$91.5K	0.17%	33
2014 Q1	$538K	Hold	56,666	–	–	0.35%	38
2013 Q4	$368K	Hold	56,666	–	–	0.27%	35
2013 Q3	$429K	Sell	56,666 -10,000	-15%	-$107K	0.38%	42
2013 Q2	$771K	Buy	+66,666	New	+$525K	0.56%	43

Other funds holding CYTK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $2.43B AUM 103.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare Value Capital's CYTK Position: Q4 2016 in Review

Healthcare Value Capital sold out of Cytokinetics (CYTK) in Q4 2016, closing a stake of 100,000 shares — an estimated $918K sold.

Healthcare Value Capital first reported a position in CYTK in Q2 2013 and held it in 13 quarters. The position peaked at $1.05M in Q4 2015. 101 funds tracked by Wall St. Rank hold CYTK as of Q4 2016.

Healthcare Value Capital reported no remaining Cytokinetics position as of Q4 2016 after selling out during the quarter.
Healthcare Value Capital sold 100,000 Cytokinetics shares in Q4 2016, an estimated $918K.
Healthcare Value Capital first reported a position in Cytokinetics in Q2 2013 and held it in 13 quarters.
Healthcare Value Capital's Cytokinetics position peaked at $1.05M in Q4 2015.
101 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2016.

Based on Healthcare Value Capital's 13F filing for Q4 2016, filed 10 Feb 2017.